

ANGPTL3 Antibody

Rabbit mAb Catalog # AP92490

Specification

ANGPTL3 Antibody - Product Information

Application WB, ICC
Primary Accession O9Y5C1
Reactivity Rat

Clonality Monoclonal

Other Names

ANG5; Angiopoietin 5; Angiopoietin like 3; ANGPT5; ANGPTL3; ANL3; FHBL2;

Isotype Rabbit IgG
Host Rabbit
Calculated MW 53637 Da

ANGPTL3 Antibody - Additional Information

Dilution **WB~~1:1000**

ICC~~N/A

Purification Affinity-chromatography

Immunogen A synthesized peptide derived from human

ANGPTL3

Description Acts in part as a hepatokine that is

involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to

food intake (By similarity). Has a

stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL

activity.

Storage Condition and Buffer Rabbit IgG in phosphate buffered saline ,

pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid

freeze / thaw cycle.

ANGPTL3 Antibody - Protein Information

Name ANGPTL3

Synonyms ANGPT5

Function

Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism (PubMed:11788823,



PubMed:12909640, PubMed: 23661675, $PubMed: 25495645).$ Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N- terminal domain, and is not inhibited by GPIHBP1 (PubMed: 12097324, PubMed:19318355, PubMed:20581395). Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids (PubMed: 17110602, PubMed:19028676). Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol (PubMed: 12565906). Suppresses LPL specifically in oxidative tissues which is

required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density

Cellular Location

Secreted {ECO:0000250, ECO:0000305|PubMed:11877390}. Cell projection, lamellipodium {ECO:0000250|UniProtKB:Q9R182}. Note=Colocalized with HSPG2 and activated ITGB3 on podocytes. {ECO:0000250|UniProtKB:Q9R182}

lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway

implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity).

Tissue Location

Expressed principally in liver. Weakly expressed in kidney. Binds to adipocytes. Increased expression and colocalization with activated ITGB3 in glomeruli of patients with nephrotic syndrome showing effaced podocyte foot processes (at protein level)

ANGPTL3 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

ANGPTL3 Antibody - Images



